Author: Larry Magee

Transformation Clark weigh-in No.6
Follow Clarks journey as he goes through his body transformation in 12 weeks. Clark is following 'The Metabolic Acceleration Programme' CLICK BELOW to get your copy… www.boostmymetabolicrate.com If you've been thinking about transforming your body, and by that i mean losing weight, getting toned, losing bodyfat, or getting fitter, take a look through the 'Transformation Clark' videos to get some real life inspiration. My friend Clark came to me (Adrian Woodall, personal trainer of 10 years) and said "ok, i want to lose weight, get fit, and sort my diet and exercise out". "Great" i said, "I've just written the perfect programme for you" Its called 'The Metabolic Acceleration Programme' www.boostmymetabolicrate.com He agreed to go through the programme, which includes a fully illustrated, progressive 12 week exercise programme and a nutrition plan to compliment this and guarantee results. Right from the start we thought we would video the weigh-ins, and other parts of Clarks journey as it happened. To keep updated (or to view the archive and see the journey from the start) on 'Transformation Clark' click the link below… www.boostmymetabolicrate.com
Views:
3
0
ratings
Time:04:53 More inEducation

Dr. Grothey Discusses Novel Agents for Colorectal Cancer
Axel Grothey, MD, Professor of Oncology, Consultant, Medical Oncology, Mayo Clinic, discusses the novel agents being investigated for colorectal cancer (CRC). There has not been a new agent for CRC since the approval of cetuximab and bevacizumab 7 1/2 years ago. In recent months there have been numerous advances in what was previously a very stagnant field. One of the most important discoveries is that KRAS mutated tumors do not respond to epidermal growth factor receptor (EGFR) inhibitor drugs such as cetuximab and panitumumab. Aflibercept, a novel agent currently under investigation, binds to the VEGF-A ligand, VEGF-B, and the placental growth factor (PIGF). Adding aflibercept to FOLFIRI in metastatic CRC patients resulted in significantly improved outcomes in the second-line setting. The oral multikinase inhibitor named regorafenib demonstrated overall survival in heavily pretreated metastatic CRC; these patients currently do not have any clinical options. The data from the phase III trial, which was stopped early because of positive data, will be released at ASCO GI 2012.
Views:
44
0
ratings
Time:01:48 More inScience & Technology

Fast Weight Loss Tips
bit.ly Here are the top 3 Fast Weight Loss Tips. Find more fitness videos at or own this video for just $0.75! Start your new years resolution off right with a healthy lifestyle diet and exercise plan. These free weight loss diet tips will help you lose fat and weight fast! Happy New Years and clip this video for future art reference. Check Out Diet.com Video! Diet.com: Subscribe to Our YouTube Channel – Go behind the scenes w/ Sarah's Blog- Twitter twitter.com Facebook: iTunes: tinyurl.com Cool!
Views:
0
0
ratings
Time:03:10 More inEntertainment